In the phase I study targeting NSCLC patients (NCT03215810), both CD8 and CD4 T cells capable of recognizing cancer‐testis antigens and neoantigens were found in TIL infusion products, and these cells were strongly associated with objective clinical response.[52, 68] This suggests that the greater the clonal diversity within TIL products, the more diverse the arsenal against tumor antigens, thereby increasing the likelihood of therapeutic response. This evidence concerns the gene CD8A and neoplasm.